One of the most unique transactions in the public marijuana industry may be misunderstood by market participants, according to one of the people behind the deal.

The leading executives of Canopy Growth (NYSE:CGC,TSX:WEED) and Acreage Holdings (CSE:ACGR.U,OTCQX:ACRGF) held the stage together at the kickoff of the MJBizConINT’L event in Toronto to discuss the state of consolidation in the cannabis space.

Kevin Murphy, CEO of Acreage, told the audience at the show on Thursday (September 5) that Canopy has an obligation to its deal with the multi-state operator.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“Canopy has an obligation to exercise that option, and given the disparity between where parity is today and where our stock trades, clearly it’s either misunderstood or people believe that option is not a two way mandate,” Murphy said during the panel.

In April, the two marijuana firms announced an acquisition plan by way of a transaction valued at US$3.4 billion. Part of the deal states that Canopy Growth will complete the transaction should cannabis become legal in the US.

However, the companies have hinted that the passing of the STATES Act, a policy that has opened the doors for states to regulate their cannabis programs without federal interference, could also trigger the acquisition.

Mark Zekulin, CEO of Canopy Growth, added that if an investor today believes the triggering action for the deal — the legalization of cannabis in the US — is set to take place, investing in his firm represents future exposure to the entire US market.

Canopy Growth has made moves to the US space with investment in hemp development.

“Canopy has an option to buy Acreage, but it’s actually I would call it a forced option,” said Zekulin. “If you believe the triggering event will occur … in the next six, seven years, then it’s not a question of Canopy might exercise its option — Canopy will exercise its option, Canopy has to exercise its option.”

After the dismissal of Bruce Linton, former co-CEO and spokesperson for Canopy Growth, Zekulin assumed the role of CEO. He is set to hold his position until the cannabis firm finds a new leader.

The deal has also opened the door for Acreage to use brands and intellectual property from Canopy Growth. Zekulin said the partnership and brand sharing goes “much deeper” than just a store name.

The duo briefly talked about the lessons shared between market players from the US and Canadian markets. Murphy said the US’ biggest export for this industry will be brands and brand appeal.

He hinted that there is a chance there will be recognizable brand development in the US that later appears in the Canadian market.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Acreage Holdings is a client of the Investing News Network. This article is not paid-for content.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.

Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.

Keep reading... Show less

The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement

Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination

Keep reading... Show less

Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising

Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.

In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.

Keep reading... Show less

Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.

Keep reading... Show less